NGNENeurogene Inc.
$26.44+13% 1Y
$26.44
$16.3752 weeks$42.88
Price
+13%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 2% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for NGNE today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$417.8M
1 year+13%
5 years-82%
Charts
As reported to the SEC, without any scoring.
For the full year FY2025, revenue was $0 (−100% year on year) and net income −$90M. The next results filing is expected around Nov 12, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 2, 2026On June 30, 2026, Neurogene Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC, as representatives of the underwriters named therein (the “Underwriters”), to issue and sell …Material agreement entered · Form 8-K
- Jun 29, 2026On June 29, 2026, the Company also made publicly available a presentation announcing positive, updated clinical data from its Phase 1/2 trial evaluating NGN-401gene therapy for the treatment of females with Rett syndrome.Regulation FD disclosure · Form 8-K
- Apr 20, 2026Effective as of April 20, 2026, the Board of Directors (the “Board”) of Neurogene Inc. (the “Company”), upon recommendation of the Board's Nominating and Corporate Governance Committee (the "Nominating Committee"), took action pursuant to the Company's Amended and Restated Bylaws to expand the Board to seven directors …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.